Pharmaceutical major Strides Acrolab has announced that it has received regulatory sanction for two of its drugs used in the treatment of potentially life-threatening infections.

According to sources, the conglomerate has got approval from US Food and Drug Administration for Sterile Vancomycin in two different capacities.

The products are licensed to Akron-Strides LLC, which is a joint venture between Akron Inc and Strides Arcolab.

While commenting on the approval, Mr Ravi Seth, Strides Chief Executive Officer stated,  “Product launch is to happen in the first half of 2009.”

Sterile Vancomycin is indicated in the treatment of potentially life-threatening infections, which cannot be treated with other effective antimicrobial drugs.